Comparison 5. Sensitivity analysis 1: all trials.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Failure to control bleeding	16	1648	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.06, 0.02]
1.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	‐0.23 [‐0.44, ‐0.03]
1.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.12, 0.09]
1.3 EVS compared with somatostatin	4	237	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.07, 0.05]
1.4 EVS compared with octreotide	10	1128	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.07, 0.04]
2 Five‐day failure rate	9	926	Risk Difference (M‐H, Random, 95% CI)	‐0.05 [‐0.10, 0.01]
2.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
2.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.14, 0.11]
2.3 EVS compared with somatostatin	4	366	Risk Difference (M‐H, Random, 95% CI)	‐0.08 [‐0.20, 0.03]
2.4 EVS compared with octreotide	4	341	Risk Difference (M‐H, Random, 95% CI)	‐0.05 [‐0.14, 0.04]
3 Rebleeding	16	1753	Risk Difference (M‐H, Random, 95% CI)	0.01 [‐0.03, 0.05]
3.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	0.04 [‐0.17, 0.26]
3.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	0.01 [‐0.11, 0.12]
3.3 EVS compared with somatostatin	5	406	Risk Difference (M‐H, Random, 95% CI)	‐0.05 [‐0.13, 0.03]
3.4 EVS compared with octreotide	9	1064	Risk Difference (M‐H, Random, 95% CI)	0.02 [‐0.03, 0.08]
4 Rebleeding before other elective treatments	10	1071	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.06, 0.02]
4.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
4.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.00 [‐0.09, 0.09]
4.3 EVS compared with somatostatin	4	366	Risk Difference (M‐H, Random, 95% CI)	‐0.05 [‐0.13, 0.02]
4.4 EVS compared with octreotide	5	486	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.07, 0.05]
5 Mortality	17	1817	Risk Difference (M‐H, Random, 95% CI)	‐0.02 [‐0.06, 0.02]
5.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	‐0.11 [‐0.34, 0.11]
5.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	‐0.08 [‐0.19, 0.03]
5.3 EVS compared with somatostatin	5	406	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.10, 0.05]
5.4 EVS compared with octreotide	10	1128	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.06, 0.04]
6 Mortality before other elective treatments	7	681	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.05, 0.03]
6.1 EVS compared with vasopressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6.2 EVS compared with terlipressin	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]
6.3 EVS compared with somatostatin	2	150	Risk Difference (M‐H, Random, 95% CI)	‐0.03 [‐0.13, 0.07]
6.4 EVS compared with octreotide	5	531	Risk Difference (M‐H, Random, 95% CI)	‐0.00 [‐0.05, 0.04]
7 Transfusions	8	849	Mean Difference (IV, Random, 95% CI)	‐0.24 [‐0.54, 0.07]
7.1 EVS compared with vasopressin	0	0	Mean Difference (IV, Random, 95% CI)	0.0 [0.0, 0.0]
7.2 EVS compared with terlipressin	1	219	Mean Difference (IV, Random, 95% CI)	0.20 [‐1.01, 1.41]
7.3 EVS compared with somatostatin	2	239	Mean Difference (IV, Random, 95% CI)	0.48 [‐1.79, 2.75]
7.4 EVS compared with octreotide	5	391	Mean Difference (IV, Random, 95% CI)	‐0.20 [‐0.60, 0.20]
8 Adverse events	12	1178	Risk Difference (M‐H, Random, 95% CI)	0.08 [0.03, 0.14]
8.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	‐0.01 [‐0.15, 0.14]
8.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	0.10 [‐0.02, 0.21]
8.3 EVS compared with somatostatin	4	366	Risk Difference (M‐H, Random, 95% CI)	0.14 [0.07, 0.22]
8.4 EVS compared with octreotide	6	529	Risk Difference (M‐H, Random, 95% CI)	0.06 [‐0.03, 0.15]
9 Serious adverse events	5	602	Risk Difference (M‐H, Random, 95% CI)	0.05 [0.02, 0.08]
9.1 EVS compared with vasopressin	1	64	Risk Difference (M‐H, Random, 95% CI)	0.03 [‐0.05, 0.11]
9.2 EVS compared with terlipressin	1	219	Risk Difference (M‐H, Random, 95% CI)	0.03 [‐0.03, 0.09]
9.3 EVS compared with somatostatin	3	319	Risk Difference (M‐H, Random, 95% CI)	0.07 [0.01, 0.13]
9.4 EVS compared with octreotide	0	0	Risk Difference (M‐H, Random, 95% CI)	0.0 [0.0, 0.0]